Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
A reverse discounted cash flow is not shown for a company with no positive EBITDA.
No positive EBITDA in the recent record, so there is no return on capital to compare against its cost.
Classified from the filings: EBITDA negative in each of the last 2 years.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$78.8M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Modest payoff on reinvested capital. Current ROIC on all capital: 34%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $548.5M 100.0% | $630.2M 100.0% | $838.0M 100.0% | $426.4M 100.0% | $356.1M 100.0% | $228.0M 100.0% | $204.9M 100.0% | $214.1M 100.0% | $241.2M 100.0% | $216.1M 100.0% |
| Cost of Revenue | $336.3M 61.3% | $348.9M 55.4% | $384.4M 45.9% | $311.1M 73.0% | — | — | — | — | $169.8M 70.4% | $149.1M 69.0% |
| Cost of Products | — | — | — | — | — | — | — | — | $169.8M 70.4% | $149.1M 69.0% |
| Research & Development | $148.3M 27.0% | $212.1M 33.7% | $302.0M 36.0% | $386.9M 90.7% | $299.1M 84.0% | $174.8M 76.7% | $138.2M 67.4% | $114.2M 53.3% | $75.5M 31.3% | $66.9M 30.9% |
| Selling, General & Admin | $66.7M 12.2% | $64.3M 10.2% | $79.8M 9.5% | $92.2M 21.6% | $89.3M 25.1% | $50.0M 21.9% | $39.2M 19.1% | $30.9M 14.4% | $24.0M 9.9% | $21.6M 10.0% |
| Total Operating Expenses | $587.7M 107.1% | $673.9M 106.9% | $819.6M 97.8% | $834.1M 195.6% | $684.4M 192.2% | $424.6M 186.3% | $351.3M 171.4% | $306.8M 143.3% | $294.6M 122.1% | $262.8M 121.6% |
| Operating Income | -$39.2M -7.1% | -$43.7M -6.9% | $18.4M 2.2% | -$407.7M -95.6% | -$328.3M -92.2% | -$196.7M -86.3% | -$146.4M -71.4% | -$92.6M -43.3% | -$53.4M -22.1% | -$46.7M -21.6% |
| Interest Expense | $2.9M 0.5% | $2.9M 0.5% | $759K 0.1% | $652K 0.2% | $592K 0.2% | $787K 0.3% | $1.0M 0.5% | $1.0M 0.5% | $1.5M 0.6% | $1.6M 0.8% |
| Interest & Investment Income | $49.9M 9.1% | $40.1M 6.4% | $36.1M 4.3% | $9.6M 2.3% | $2.1M 0.6% | $3.2M 1.4% | $4.9M 2.4% | $6.0M 2.8% | $1.2M 0.5% | $502K 0.2% |
| Other Income (Expense), net | $61.0M 11.1% | $42.6M 6.8% | $39.9M 4.8% | -$2.7M -0.6% | -$8.7M -2.5% | $6.9M 3.0% | $5.3M 2.6% | $6.0M 2.8% | -$119K -0.0% | -$659K -0.3% |
| Pretax Income | $498.7M 90.9% | -$1.1M -0.2% | $58.3M 7.0% | -$410.4M -96.3% | -$215.7M -60.6% | -$189.7M -83.2% | -$141.1M -68.9% | -$86.7M -40.5% | -$53.5M -22.2% | $20.5M 9.5% |
| Income Tax Expense | $63.6M 11.6% | $7.2M 1.1% | $4.5M 0.5% | -$283K -0.1% | $11.9M 3.3% | $4.8M 2.1% | $3.3M 1.6% | $4.0M 1.9% | $3.1M 1.3% | $4.3M 2.0% |
| Net Income | $456.9M 83.3% | $37.7M 6.0% | $100.8M 12.0% | -$360.8M -84.6% | -$194.6M -54.7% | -$125.7M -55.2% | -$106.0M -51.7% | -$74.8M -34.9% | -$26.7M -11.1% | $11.7M 5.4% |
| Per Share | ||||||||||
| EPS (Basic) | $0.53 | $0.04 | $0.12 | -$0.43 | -$0.25 | -$0.18 | -$0.16 | -$0.11 | -$0.04 | $0.20 |
| EPS (Diluted) | $0.52 | $0.04 | $0.12 | -$0.43 | -$0.25 | -$0.18 | -$0.16 | -$1.13 | -$0.43 | $0.20 |
| Weighted Avg Shares (Basic) | 858.3M | 855.4M | 849.7M | 847.1M | 792.7M | 697.9M | 665.7M | 664.3M | 617.2M | 59.7M |
| Weighted Avg Shares (Diluted) | 872.9M | 872.8M | 869.2M | 847.1M | 792.7M | 697.9M | 665.7M | 66.4M | 61.7M | 60.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $71.3M covers the $25.0M due within a year 2.9× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (20-F).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~3.1% on $93.2M of debt.
Cash of $71.3M fully covers short-term debt of $25.0M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Ranked against 24 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RYTM | $6.4B | — | — | 33.8× | 45.8% | 89.7% | -104% | -141% | -79.5% | — | 46 |
| LGND | $6.3B | 51.8× | 82.3× | 23.6× | 60.4% | — | 46.4% | 12.2% | 12.2% | -2.3× | 97 |
| PTCT | $5.4B | 8.3× | 5.2× | 3.1× | 115% | — | 39.4% | -332% | 839% | -0.8× | 62 |
| TVTX | $4.8B | — | — | 9.7× | 110% | 97.9% | -5.2% | -22.2% | -22.2% | — | 45 |
| INDV | $4.2B | 21.5× | 15.8× | 3.4× | 4.3% | 80.2% | 16.9% | -214% | 95.0% | 0.5× | 52 |
| ARQT | $4.0B | — | — | 10.7× | 91.3% | 90.2% | -4.3% | -8.5% | -5.4% | — | 50 |
| OGN | $3.6B | 19.2× | — | 0.6× | -2.9% | 53.3% | 3.0% | 24.9% | 2.0% | — | 150 |
| ACAD | $3.6B | 9.0× | 32.2× | 3.3× | 11.9% | 91.7% | 36.5% | 31.9% | 31.9% | -1.7× | 61 |
| BHC | $3.3B | 21.2× | 11.3× | 0.3× | 6.7% | — | 1.5% | -28.3% | 0.8% | 9.7× | 35 |
| ZLAB | $2.8B | — | — | 6.0× | 15.3% | 58.6% | -38.1% | -24.5% | -19.1% | — | 8 |
| SUPN | $2.4B | — | 78.8× | 3.4× | 8.6% | 89.6% | -5.4% | -3.6% | -3.6% | -4.4× | 60 |
| HCM | $2.4B | 26.1× | — | 4.3× | -13.0% | 38.7% | 83.3% | 36.9% | 34.3% | — | 8 |
| PBH | $2.3B | 12.5× | 9.5× | 2.1× | -4.3% | 54.7% | 17.5% | 10.1% | 6.6% | 2.7× | 57 |
| AUPH | $2.3B | 8.3× | 17.8× | 8.1× | 20.4% | 88.5% | — | 49.4% | 49.4% | -0.6× | 41 |
| HRMY | $2.2B | 14.2× | — | 2.6× | 21.5% | 77.2% | 18.3% | 18.2% | 15.3% | — | 67 |
| SDGR | $2.2B | — | — | 8.8× | 23.3% | 55.7% | -40.4% | -28.4% | -28.4% | — | 58 |
| AGIO | $2.2B | — | — | 41.1× | 48.0% | 88.3% | -764% | -34.6% | -34.6% | — | 35 |
| PRGO | $2.2B | — | — | 0.5× | -2.8% | 35.1% | -33.5% | -48.6% | -21.7% | — | 72 |
| SRPT | $2.0B | — | — | 0.9× | 15.6% | 98.8% | -32.5% | -62.5% | -36.2% | — | 47 |
| ANIP | $1.7B | 22.0× | 14.2× | 1.9× | 43.8% | — | 8.9% | 14.5% | 9.2% | 0.2× | 46 |
| OCUL | $1.6B | — | — | 30.9× | -18.5% | 87.3% | -512% | -40.6% | -40.6% | — | 39 |
| PAHC | $1.6B | 16.0× | 6.2× | 1.0× | 17.1% | 33.8% | 6.6% | 25.9% | 25.9% | -0.3× | 41 |
| INVA | $1.5B | 6.5× | — | 3.7× | 14.7% | 74.8% | 65.9% | 23.1% | 19.0% | — | 54 |
| ETON | $1.5B | — | — | 19.2× | 105% | 53.5% | -5.8% | -17.6% | -8.1% | — | 36 |
| ANAB | $1.5B | — | 5.8× | 6.2× | 157% | — | -5.6% | -35.6% | -35.6% | -0.6× | 28 |
Peers = companies sharing HCM's sector (Pharmaceutical Preparations) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
No trend data available for this metric.
Top 8 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-20 | 2 co-filers Acting CEO and CFO | Otherindirect | 30,157 | $0.00 | — |
| 2026-05-20 | 2 co-filers Group General Counsel | Otherindirect | 7,445 | $0.00 | — |
| 2026-05-20 | 2 co-filers CEO and CSO | Otherindirect | 132,864 | $0.00 | — |
| 2026-05-20 | 2 co-filers Deputy Chief Financial Officer | Otherindirect | 5,176 | $0.00 | — |
| 2026-05-20 | 2 co-filers Deputy Chief Financial Officer | Otherindirect | 8,863 | $0.00 | — |
| 2026-05-20 | 2 co-filers Acting CEO and CFO | Otherindirect | 26,307 | $0.00 | — |
| 2026-05-20 | 2 co-filers CEO and CSO | Otherindirect | 75,140 | $0.00 | — |
| 2026-05-20 | 2 co-filers Group General Counsel | Otherindirect | 7,644 | $0.00 | — |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-30
Where each multiple sits in its own 10-yr range · 27th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 10-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 37% against ROIC 34% — 3% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is 45.7% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | — | — | — | 73.0 | 45.9 | 55.4 | 61.3 |
| R&D | 53.3 | 67.4 | 76.7 | 84.0 | 90.7 | 36.0 | 33.7 | 27.0 |
| SG&A | 14.4 | 19.1 | 21.9 | 25.1 | 21.6 | 9.5 | 10.2 | 12.2 |
| Operating Income | -43.3 | -71.4 | -86.3 | -92.2 | -95.6 | 2.2 | -6.9 | -7.1 |
| Income Tax | 1.9 | 1.6 | 2.1 | 3.3 | -0.1 | 0.5 | 1.1 | 11.6 |
| Net Income | -34.9 | -51.7 | -55.2 | -54.7 | -84.6 | 12.0 | 6.0 | 83.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on HCM: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Earns -21.3pts against its cost of capital — capital is being consumed, not created.
| Period | ROIC | Cost of capital | Spread |
|---|---|---|---|
| FY2019 | -64.4% | 8.7% (today's — no rate published for this year) | -73.1pts |
| FY2020 | -61.1% | 8.7% (today's — no rate published for this year) | -69.9pts |
| FY2021 | -43.2% | 6.7% | -49.9pts |
| FY2022 | -110.0% | 10.3% | -120.3pts |
| FY2023 | 3.0% | 10.2% | -7.2pts |
| FY2024 | -5.5% | 10.3% | -15.8pts |
| FY2025 | -2.8% | 7.2% | -10.0pts |
| Now | 34.3% | 8.7% | 25.6pts |
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 31.0% | -21.6% | 5.4% |
| FY2017 | 29.6% | -22.1% | -11.1% |
| FY2018 | not reported | -43.3% | -34.9% |
| FY2019 | not reported | -71.4% | -51.7% |
| FY2020 | not reported | -86.3% | -55.2% |
| FY2021 | not reported | -92.2% | -54.7% |
| FY2022 | 27.0% | -95.6% | -84.6% |
| FY2023 | 54.1% | 2.2% | 12.0% |
| FY2024 | 44.6% | -6.9% | 6.0% |
| FY2025 | 38.7% | -7.1% | 83.3% |
$3M of goodwill — 1% of invested capital. The gap is what was paid above the fair value of what was bought; it is real capital shareholders provided, so neither bar is the whole answer.
ROIC ex-goodwill is -12.73% against -12.59% reported — the return is earned on a capital base inflated by what was paid for acquisitions, not by the operating business alone.
Cash conversion of 0.41x sits below the level that would make the earnings clearly cash-backed.
The cash conversion cycle has lengthened +13 days over 3 years to 80 — that many more days of the company's own cash funding the same volume of business.
Missing from our data, so excluded from this answer: share_based_compensation.
Debt is present but there is no positive EBITDA or no reported interest expense, so coverage cannot be measured.
Ladder as of 2025-12-31 (20-F); cash from the 2025-12-31 balance sheet; FCF from FY2025. Free cash flow is negative, so projected resources fall rather than accumulate.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
Missing from our data, so excluded from this answer: ebitda.
At $13.59, free cash flow must compound -0.85%/yr for 10 years. It has no positive compounding record to compare against.
The implied rate of -0.85% has not been achieved in any of the last 1 years.
| Step | Amount | Running total |
|---|---|---|
| Net income | $457M | $457M |
| Share-based comp | not reported | not reported |
| Other non-cash & working capital | −$522M | −$65M |
| Operating cash flow | −$65M | −$65M |
| Capex | −$14M | −$79M |
| Free cash flow | −$79M | −$79M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | 11.3% | 15.6% | 4.3 points |
| FY2021 | 56.2% | 74.6% | 18.4 points |
| FY2022 | 19.7% | 17.2% | -2.5 points |
| FY2023 | 96.5% | 19.3% | -77.2 points |
| FY2024 | -24.8% | 33.1% | 57.9 points |
| FY2025 | -13.0% | -18.5% | -5.6 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 73.8 days | not reported | not reported | not reported |
| FY2020 | 76.6 days | not reported | not reported | not reported |
| FY2021 | 85.7 days | not reported | not reported | not reported |
| FY2022 | 83.9 days | 66.5 days | 83.4 days | 67 days |
| FY2023 | 50.9 days | 47.7 days | 34.5 days | 64.1 days |
| FY2024 | 90.1 days | 52.7 days | 44.5 days | 98.3 days |
| FY2025 | 84.3 days | 44.6 days | 49.4 days | 79.6 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | -5.4 percent |
| FY2020 | -8.8 percent |
| FY2021 | 0.7 percent |
| FY2022 | -9.0 percent |
| FY2023 | -9.3 percent |
| FY2024 | 2.9 percent |
| FY2025 | 29.8 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.